1.5 Abstract in Rivista Home page tipologia

Sfoglia AAA

Iscriviti a questa tipologia per ricevere ogni giorno la notifica via e-mail di nuovi arrivi RSS Feed RSS Feed RSS Feed
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1 a 20 di 1207
 successivo >
TitoloData di depositoAutore(i)
L-ARGININE AND CARDIOPLEGIA: A PROSPECTIVE RANDOMIZED STUDY27-apr-2020Colagrande, L; Formica, F; Porta, F; Brustia, M; Avalli, L; Sangalli, F; Paolini, G
DIASTOLIC FUNCTION EVALUATED BY TISSUE DOPPLER ANALYSIS AND ARTERIAL STIFFNESS AFTER CARDIAC REVASCULARIZATION27-apr-2020Montemerlo, E; Cafro, A; Capra, A; Canova, P; Pozzi, M; Betelli, M; Cesana, F; Calchera, I; Colombo, V; Formica, F; Paolini, G; Giannattasio, C; Mancia, G
Favorable Survival of In-Hospital Compared with Out-of-Hospital Refractory Cardiac Arrest Patients Treated with Extracorporeal Membrane Oxygenation: An Italian Tertiary Care Center Experience27-apr-2020Avalli, L; Greco, G; Sangalli, F; Galbiati, L; Trabucchi, M; Formica, F; Costa, C; Ristagno, G; Fumagalli, R
Effects of papaverine and glyceril-trinitrate/verapamil solution on internal thoracic artery flow: a prospective randomized study27-apr-2020Brustia, M; Formica, F; Colagrande, L; Corti, F; Bosisio, E; Paolini, G.
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY26-apr-2020Musolino, A; Bella, MA; Michiara, M; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Camisa, R; Neri, TM; Ardizzoni, A
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study26-apr-2020Musolino, A; Boggiani, D; Bella, MA; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Michiara, M; Ardizzoni, A
DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC)23-apr-2020Bella, MA; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Neri, TM; Savi, M; Bandini, N; Franciosi, V; De Lisi, V; Sgargi, P; Ardizzoni, A; Cascinu, S
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC)23-apr-2020Bella, MA; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Bandini, N; Franciosi, V
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC)23-apr-2020Bella, MA; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Cappelletti, M; Neri, TM; Savi, M; Bandini, N; De Lisi, V; Sgargi, P; Ardizzoni, A
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer23-apr-2020Musolino, A; Naldi, N; Bortesi, B; Capelletti, M; Pezzuolo, D; Franciosi, D; Missale, G; Laccabue, D; Camisa, R; Ardizzoni, A
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC)23-apr-2020Duchnowska, Renata; Jarzab, Michal; Zebracka, Jadwiga; Matkowski, Rafal; Kowalczyk, Anna; Radecka, Barbara; Foszczynska-Kloda, Malgorzata; Musolino, Antonino; Czartoryska-Arlukowicz, Bogumila; Litwiniuk, Maria Malgorzata; Szablowska-Siwik, Sylwia; Karczmarek-Borowska, Bozenna; Sosinska-Mielcarek, Katarzyna; Chmielowska, Ewa; Olszewski, Wojciech P; Patera, Janusz; Zawrocki, Anton; Rusinek, Dagmara; Jassem, Jacek; Biernat, Wojciech
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study23-apr-2020Musolino, A; Sikokis, A; Boggiani, D; Rimanti, A; Pellegrino, B; Silini, EM; Campanini, N; Barbieri, E; Cortesi, L; Panebianco, M; Porzio, R; Frassoldati, A; Sgargi, P; Falcini, F; Michiara, M
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors23-apr-2020Migliari, S; Sammartano, A; Pellegrino, B; Regina, V; Cavazzini, D; Ottonello, S; Missale, G; Musolino, A; Ruffini, L
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER23-apr-2020Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)23-apr-2020Musolino, Antonino; Porzio, Rosa; Rubino, Daniela; Frassoldati, Antonio; Caldara, Alessia; Schirone, Alessio; Gori, Stefania; Piacentini, Federico; Berardi, Rossana; Brandes, Alba Ariela; Cavazzini, Giovanna; Foglietta, Jennifer; Villa, Federica; Pellegrino, Benedetta; Camisa, Roberta; Todeschini, Renata; Tognetto, Michele; Naldi, Nadia; Baldari, Daniela; Montemurro, Filippo
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer23-apr-2020Conte, P.; Conte, P.; Bisagni, G.; Frassoldati, A.; Brandes, A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Musolino, A.; Garrone, O.; Donadio, M.; Cavazzini, G.; Turletti, A.; Zamagni, C.; Danese, S.; Ferro, A.; Piacentini, F.; Balduzzi, S.; D'Amico, R.; Guarneri, V.
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)23-apr-2020Musolino, A; Gori, S; Cavanna, L; Graiff, C; Frassoldati, A; Bria, E; Bisagni, G; Zambelli, A; Partesotti, G; Brandes, A; Bonetti, A; Moscetti, L; Zamagni, C; Rocca, A; Generali, D; Montemurro, F; Gianni, L; Tognetto, M; Maglietta, G; Todeschini, R
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio23-apr-2020Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R.
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial23-apr-2020Dieci, M. V.; Conte, P. F.; Bisagni, G.; Brandes, A. A.; Frassoldati, A.; Cavanna, L.; Musolino, A.; Giotta, F.; Rimanti, A.; Garrone, O.; Bertone, E.; Cagossi, K.; Sarti, S.; Ferro, A.; Omarini, C.; Maiorana, A.; Orvieto, E.; Sanders, M.; D'Amico, R.; Guarneri, V.
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)23-apr-2020Musolino, A; Cavanna, L; Boggiani, D; Zamagni, C; Frassoldati, A; Caldara, A; Rocca, A; Gori, S; Piacentini, F; Berardi, R; Brandes, AA; Foglietta, J; Villa, F; Pellegrino, B; Todeschini, R; Tognetto, M; Naldi, N; Bortesi, B; Boni, L; Montemurro, F; Ardizzoni, A
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1 a 20 di 1207
 successivo >

Scopri

Per lingua
Accesso al fulltext
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2020